INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Inclusion Criteria: * Ability to comprehend and willingness to sign an ICF. * Willing and able to conform to and comply with all Protocol requirements. * Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian cancer, TNBC, CRPC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC) that progressed after treatment with available therapies (including anti PD-(L)1 therapy (if applicable). * Willingness to undergo pre- and on-treatment tumor biopsy. * Have CD8 T-cell-positive tumors. * Presence of measurable disease according to RECIST v1.1. * ECOG performance status 0 to 1. * Life expectancy \> 12 weeks. * Willingness to avoid pregnancy or fathering children based. * Acceptable laboratory parameters Exclusion Criteria: * Clinically significant cardiac disease. * Known or active CNS metastases and/or carcinomatous meningitis. * Active or inactive autoimmune disease or syndrome that required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease.. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses \> 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment. * Known additional malignancy that is progressing or requires active treatment,or history of other malignancy within 2 years of the first dose of study treatment. * Has no…